Browsing Tag
Enanta Pharmaceuticals
3 posts
Are investors underestimating Enanta after Jefferies’ upgrade on RSV drug zelicapavir?
Jefferies upgrades Enanta Pharmaceuticals (NASDAQ: ENTA) to Buy on zelicapavir RSV trial promise; stock outlook, financing, and market sentiment inside.
Enanta (NASDAQ: ENTA) prices $65m offering at $10 per share — Is this a lifeline or a warning sign?
Enanta Pharmaceuticals (NASDAQ: ENTA) raises $65M in stock offering at $10 per share. Explore dilution risks, investor sentiment, and future outlook.
Enanta Pharmaceuticals to reveal Phase 2b RSV trial results—can zelicapavir change treatment for high-risk adults?
Enanta Pharmaceuticals will present Phase 2b zelicapavir results in RSV high-risk adults. See why this trial matters for investors, patients, and the RSV market.